14 Biotechnology Stocks to Sell Now

This week, the ratings of 14 Biotechnology stocks on Portfolio Grader are down. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

This week, ACADIA Pharmaceuticals Inc.’s (ACAD) rating worsens to a D from the company’s C rating a week ago. ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. The company also gets F’s in return on equity. For more information, get Portfolio Grader’s complete analysis of ACAD stock.

Flexion Therapeutics, Inc. (FLXN) slips from a C to a D this week. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of FLXN stock.

Epizyme, Inc. (EPZM) declines this week from a C to a D. The company also gets F’s in sales growth, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of EPZM stock.

This week, Vanda Pharmaceuticals Inc. (VNDA) drops from a C to a D rating. Vanda Pharmaceuticals Inc. is a biopharmaceutical company focusing on the development and commercialization of clinical-stage drug candidates for central nervous system disorders, with worldwide commercial rights to two product candidates in clinical development. The company also gets F’s in earnings revisions, earnings momentum, and return on equity. For more information, get Portfolio Grader’s complete analysis of VNDA stock.

Merrimack Pharmaceuticals, Inc. (MACK) gets weaker ratings this week as last week’s C drops to a D. Merrimack Pharmaceuticals, Inc. is focused on the discovery, development and commercialization of drugs for the treatment of immunological and autoimmune diseases with an initial focus on cancer. The company also gets F’s in sales growth and free cash flow. For more information, get Portfolio Grader’s complete analysis of MACK stock.

Slipping from a D to a F rating, Sangamo BioSciences, Inc. (SGMO) takes a hit this week. Sangamo BioSciences, Inc. is engaged in the research, development and commercialization of novel transcription factors for gene regulation and gene modification. The company also gets F’s in sales growth, earnings revisions, and return on equity. For more information, get Portfolio Grader’s complete analysis of SGMO stock.

ADMA Biologics, Inc. (ADMA) is having a tough week. The company’s rating falls from a D to a F. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of ADMA stock.

ProQR Therapeutics N.V. (PRQR) earns a F this week, moving down from last week’s grade of D. The company also gets F’s in earnings revisions, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of PRQR stock.

EPIRUS Biopharmaceuticals, Inc.’s (EPRS) rating weakens this week, dropping to a D versus last week’s C. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of EPRS stock.

VBI Vaccines Inc (VBIV) experiences a ratings drop this week, going from last week’s C to a D. The company also gets F’s in earnings revisions. For more information, get Portfolio Grader’s complete analysis of VBIV stock.

This is a rough week for BioCryst Pharmaceuticals, Inc. (BCRX). The company’s rating falls to D from the previous week’s C. BioCryst Pharmaceuticals, Inc. is a biotechnology company that designs, optimizes and develops novel drugs that block key enzymes involved in cancer, viral infections and autoimmune diseases. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of BCRX stock.

This week, GlobeImmune, Inc.’s (GBIM) rating worsens to a D from the company’s C rating a week ago. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of GBIM stock.

Curis, Inc. (CRIS) experiences a ratings drop this week, going from last week’s C to a D. Curis, Inc. is a drug discovery and development company that engages in the research and development of cancer therapeutics. The company also gets F’s in earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of CRIS stock.

Biota Pharmaceuticals, Inc.’s (BOTA) rating weakens this week, dropping to a F versus last week’s D. Biota Pharmaceuticals, Inc. is an anti-infective drug development company with expertise in respiratory diseases, particularly influenza. The company also gets F’s in sales growth, earnings growth, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of BOTA stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, https://investorplace.com/2016/02/14-biotechnology-stocks-to-sell-now/.

©2021 InvestorPlace Media, LLC